If patients in Asterias' dose-escalation trial have improvements in sensation (as some did in the first, low-dose cohort. Look out. VERY low float.
I couldn't agree more. First, additional warrants from BioTime after their spin-off and now additional warrants for Asterias shares--all at no cost.
I know, I know--could be worthless, but I don't think so. Liking what I'm hearing especially from Asterias--and remember, when Asterias does well, so does Geron AND BioTime. Good luck to all longs of good will.
Yes, liketheseas, ANYTHING for an EDGE. That's the mantra on Wall Street.
If they can find a way to have fewer eyes on the ball--slower reaction time--diminished expectations--it gives them just a little more of an edge.
Well, there were these words from one of the world's 4 or 5 most important researchers in the field at the most recent AGM
"In closing, based on recent findings, I firmly believe, that beta-amyloid remains the best
target for preventing and treating AD, but this must be achieved in the earliest stages of the
disease process. Based on the combined data, I continue to believe that PBT2 carries great
potential for curbing plaque and tangle formation, while also enhancing neuronal cell viability
as an AD therapeutic."
For the sake of newbies
First, from a recent article about Tanzi's "Alzheimer's -in-a-dish
"The stem cells first developed amyloid beta plaque, which is found in the brains of Alzheimer's patients, and then went on to form the tau tangles that also characterize the disease. By inhibiting an enzyme called GSK3-beta--known to phosphorylate tau in human neurons--they stopped the development of amyloid as well as tau."
Then from Masters, et al
J Neurochem. 2011 Oct;119(1):220-30. doi: 10.1111/j.1471-4159.2011.07402.x. Epub 2011 Aug 25.
The Alzheimer's therapeutic PBT2 promotes amyloid-β degradation and GSK3 phosphorylation via a metal chaperone activity.
That's absolutely right, oddusual. I'm sure that every scientist and biostatistician recognizes this--but this is a stock message board. HAHAHA
Still feeling good about the future. GLTA longs of good will.